ABCSG 47 / IMpassion030 Summary

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

Start:	07/2019
Coordinating Investigator:	Günther Steger, Vienna
Sample size:	2300 (international)
Design: (Click to enlarge)